Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Dec 7, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a rare lung condition called pulmonary Langerhans cell histiocytosis (PLCH) in adults. The main goal is to understand the long-term outcomes of patients with this condition, especially their survival rates and the factors that might affect their health over time. This is the first study of its kind in France, using a national registry to follow a large group of patients for an extended period. The researchers hope to gather important information that can help improve care for people with PLCH.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of PLCH, which can be based on a tissue biopsy or specific imaging tests of the lungs. The trial is currently recruiting participants, and anyone who joins can expect to be monitored closely over time to gather valuable data about their health. This study is significant because it aims to fill gaps in our understanding of PLCH and could lead to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>= 18 years
• • Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses
• Exclusion Criteria:
• • -